TP53 缺失通过上调 NF-κB-IFN-β-MHC-Ia 信号促进骨肉瘤对 NK 细胞的抵抗
TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mesenchymal stem cells-derived IL-6 promotes invasion and metastasis of oral squamous cell carcinoma via JAK-STAT3 signalling.
Mesenchymal stem cells-derived IL-6 promotes invasion and metastasis of oral squamous cell carcinoma via JAK-STAT3 signalling.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
结果表明,MSCs 来源的 IL-6 通过 JAK-STAT3 信号通路促进肿瘤侵袭和转移。通过 tocilizumab 阻断该通路可能是改善 OSCC 患者预后和生存率的潜在治疗方法。
口腔鳞状细胞癌(OSCC)常伴有颈部淋巴结转移。间充质干细胞(MSCs)和白细胞介素-6(IL-6)信号被认为在促进肿瘤恶性进展中发挥重要作用。MSCs与IL-6之间详细的生物学相互作用及其对OSCC转移的后续影响在很大程度上仍不清楚。本研究旨在确定MSCs来源的IL-6对肿瘤侵袭和转移的影响及其分子机制。
在体外检测了MSC来源的IL-6和tocilizumab对OSCC细胞增殖、迁移和上皮-间质转化(EMT)的影响及潜在通路。此外,构建了小鼠异种移植模型以在体内验证其生物学机制。
结果显示,MSCs和EMT相关信号在低分化OSCC组织中的表达增加。MSCs释放更高水平的IL-6,并促进OSCC细胞和实体肿瘤的增殖、侵袭和转移,这些过程由下游分子JAK和STAT3激活。
Oral squamous cell carcinoma (OSCC) is often diagnosed with cervical lymph node metastasis. Mesenchymal stem cells (MSCs) and interleukin-6 (IL-6) signalling are considered to play important roles in promoting tumour malignancy. The detailed biological interaction of MSCs and IL-6 and the subsequent effect on OSCC metastasis remain largely unclear. This study aimed to determine the effects and molecular mechanism of MSCs-derived IL-6 on tumour invasion and metastasis. SUBJECTS AND METHODS: The effects of MSC-derived IL-6 and tocilizumab on the proliferation, mobility, and epithelial-mesenchymal transition (EMT) of OSCC cells and potential pathways were detected in vitro. In addition, a murine xenograft model was generated to verify the biological mechanism in vivo.
The results showed that the expression of MSCs and EMT-related signals was increased in poorly differentiated OSCC tissues. MSCs released a higher level of IL-6 and promoted the proliferation, invasion, and metastasis of OSCC cells and solid neoplasms, which were activated by the downstream molecules JAK and STAT3.
The results indicated that MSCs-derived IL-6-promoted tumour invasion and metastasis via JAK-STAT3 signalling. Blockade of this pathway by tocilizumab may be a potential treatment to improve the prognosis and survival rate of patients with OSCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。